SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

JNJ-47965567

Item No. 21895

CAS Registry No.:	1428327-31-4
Formal Name:	2-(phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl]methyl]-3-pyridinecarboxamide
MF:	$C_{28}H_{32}N_4O_2S$
FW:	488.6
Purity:	≥98%
UV/Vis.:	λ_{max}: 251 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JNJ-47965567 is supplied as a crystalline solid. A stock solution may be made by dissolving the JNJ-47965567 in the solvent of choice. JNJ-47965567 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of JNJ-47965567 in ethanol is approximately 12.5 mg/ml and approximately 30 mg/ml in DMSO and DMF.

JNJ-47965567 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, JNJ-47965567 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. JNJ-47965567 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

JNJ-47965567 is a selective antagonist of the purinergic receptor P2X subtype 7 ($P2X_7$), a ligand-gated ion channel. Activation of P2X receptors by BzATP (Item No. 15577) induces calcium flux, which is reduced by JNJ-47965567 in 1321N1 cells transfected with recombinant $P2X_7$ human, macaque, dog, rat, or mouse protein with pIC_{50}s of 8.3, 8.6, 8.5, 7.2, or 7.5, respectively.[1] JNJ-47965567 suppresses neonatal hypoxia-induced seizures in mice and has some anticonvulsant properties in rats.[2,3] It also reduces spontaneous seizures in epileptic mice even after treatment is stopped.[4]

References

1. Bhattacharya, A., Wang, Q., Ao, H., *et al*. Pharmacological characterization of a novel centrally permeable $P2X_7$ receptor antagonist: JNJ-47965567. *Br. J. Pharmacol*. **170(3)**, 624-640 (2013).
2. Rodriguez-Alvarez, N., Jimenez-Mateos, E.M., Engel, T., *et al*. Effects of $P2X_7$ receptor antagonists on hypoxia-induced neonatal seizures in mice. *Neuropharmacology* **116(2017)**, 351-363 (2017).
3. Fischer, W.H., Franke, H., Krügel, U., *et al*. Critical evaluation of $P2X_7$ receptor antagonists in selected seizure models. *PLoS One* **11(6),** e0156468 (2016).
4. Jimenez-Pacheco, A., Diaz-Hernandez, M., Arribas-Blázquez, M., *et al*. Transient $P2X_7$ receptor antagonism produces lasting reductions in spontaneous seizures and gliosis in experimental temporal lobe epilepsy. *J. Neurosci*. **36(22)**, 5920-5932 (2016).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM